Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ10698MR)

This product GTTS-WQ10698MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Humanized; Vicugna pacos (alpaca)
RefSeq	NM_000477.7; NM_002190.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	213; 3605
UniProt ID	P02768; Q16552

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10698MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ2202MR	IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ALT-803
GTTS-WQ14957MR	IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	SHR-1210
GTTS-WQ6199MR	IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CP-870893
GTTS-WQ2928MR	IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	AMG888
GTTS-WQ15167MR	IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	T1h
GTTS-WQ927MR	IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ABBV-321
GTTS-WQ7967MR	IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	GX-17
GTTS-WQ14632MR	IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	SC0001-SCX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST